The partial glutamate antagonist amantadine is currently used in clinical practice, to reduce dyskinesia developing as a side-effect of levodopa treatment in patients suffering from Parkinson's disease (PD). This study was aimed at evaluating the antidyskinetic effect of another glutamate antagonist, memantine
BACKGROUND: Dyskinesias are some of the major motor complications that impair quality of life for pa...
Alzheimer's disease (AD) is a neurological disorder characterized by mental and behavioral changes t...
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
An increasing body of experimental evidence demonstrates that the glutamatergic system is involved i...
An increasing body of experimental evidence demonstrates that the glutamatergic system is involved i...
Striatal glutamatergic inputs are known to participate in the modulation of dopaminergic transmissio...
The long-term therapy of Parkinson’s disease (PD) with dopaminergic drugs is naturally accompanied b...
Background: Recent short-term studies suggested that aman-tadine (Ama) might ameliorate dyskinesia i...
Dyskinesias are some of the major motor complications that impair quality of life for patients with ...
To investigate the effect on survival of treatment with memantine in patients with dementia with Lew...
Glutamate is the most important excitatory neurotransmitter in the mammalian brain. Recent findings ...
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is...
Treatment of Parkinson’s disease (PD) includes the administration of dopaminergic and occasionally n...
Background: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
BACKGROUND: Dyskinesias are some of the major motor complications that impair quality of life for pa...
Alzheimer's disease (AD) is a neurological disorder characterized by mental and behavioral changes t...
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
An increasing body of experimental evidence demonstrates that the glutamatergic system is involved i...
An increasing body of experimental evidence demonstrates that the glutamatergic system is involved i...
Striatal glutamatergic inputs are known to participate in the modulation of dopaminergic transmissio...
The long-term therapy of Parkinson’s disease (PD) with dopaminergic drugs is naturally accompanied b...
Background: Recent short-term studies suggested that aman-tadine (Ama) might ameliorate dyskinesia i...
Dyskinesias are some of the major motor complications that impair quality of life for patients with ...
To investigate the effect on survival of treatment with memantine in patients with dementia with Lew...
Glutamate is the most important excitatory neurotransmitter in the mammalian brain. Recent findings ...
BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia. It is...
Treatment of Parkinson’s disease (PD) includes the administration of dopaminergic and occasionally n...
Background: Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms ...
BACKGROUND: Dyskinesias are some of the major motor complications that impair quality of life for pa...
Alzheimer's disease (AD) is a neurological disorder characterized by mental and behavioral changes t...
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
DOI
Add to ORKG